Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors

Lung Cancer

Volumn 60, Issue SUPPL. 2, 2008, Pages

  Wong, Kwok Kin ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Acquired resistance; Activating mutations; Irreversible tyrosine kinase inhibitors; Non small cell lung cancer; T790M mutation; Tyrosine kinase inhibitors

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; BIBW 2992; CL 387785; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; TOVOK;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; GENE DELETION; GENE MUTATION; HUMAN; LC 50; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 44249109706     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(08)70100-4     Document Type: Article

References (65)

1. Sako Y., Minoghchi S., and Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells. Nat Cell Biol 2 3 (2000) 168-172
2. Alroy I., and Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410 1 (1997) 83-86
3. Riese II D., and Stern D. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20 1 (1998) 41-48
4. Moghal N., and Sternberg P. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol 11 2 (1999) 190-196
5. Salomon D., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 3 (1995) 183-232
6. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 1 (2000) 12-21
7. Wells A. The epidermal growth factor receptor (EGFR)-anew target in cancer therapy. Signal 1 (2000) 4-11
8. Hynes N., and Lane H. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 5 (2005) 341-354
9. Janne P., Engelman J., and Johnson B. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23 14 (2005) 3227-3234
10. Minna J., Peyton M., and Gazdar A. Gefitinib versus cetuximab in lung cancer: round one. J Natl Cancer Inst 97 16 (2005) 1168-1169
11. Brabender J., Danenberg K., Metzger R., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 7 7 (2001) 1850-1855
12. Meyers M., Shen W., Spengler B., et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 38 2 (1988) 87-97
13. Wosikowski K., Schuurhuis D., Kops G., et al. Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res 3 12 Pt 1 (1997) 2405-2414
14. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23 14 (2005) 3235-3242
15. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 Suppl 4 (2002) 2-8
16. Rocha-Lima C., Soares H., Raez L., et al. EGFR targeting of solid tumors. Cancer Control 14 3 (2007) 295-304
17. Arteaga C. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284 1 (2003) 122-130
18. Kris M., Natale R., Herbst R., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 16 (2003) 2149-2158
19. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 12 (2003) 2237-2246
20. Shepherd F., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
21. Shepherd F. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 22 14S (2004) 7022
22. Perez-Soler R., Chachoua A., Hammond L., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 16 (2004) 3238-3247
23. Lynch T., Bell D., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
24. Paez J., Janne P., Lee J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
25. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 36 (2004) 13306-13311
26. Haringhuizen A., van Tinteren H., Vaessen H., et al. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol 15 5 (2004) 786-792
27. Miller V., Kris M., Shah N., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 6 (2004) 1103-1109
28. Janne P., Gurubhagavatula S., Yeap B., et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 44 2 (2004) 221-230
29. Simon G., Ruckdeschel J., Williams C., et al. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control 10 5 (2003) 388-395
30. Argiris A., and Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 43 3 (2004) 317-322
31. Park J., Park B., Kim J., et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 10 13 (2004) 4383-4388
32. Raymond E., Faivre S., and Armand J. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl 1 (2000) 15-23 discussion 41-2.
33. Pao W., and Miller V. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23 11 (2005) 2556-2568
34. Riely G., Politi K., Miller V., et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12 24 (2006) 7232-7241
35. Shigematsu H., and Gazdar A. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118 2 (2006) 257-262
36. Zang E., and Wynder E. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 88 3-4 (1996) 183-192
37. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 5 (2005) 339-346
38. Shigematsu H., Takahashi T., Nomura M., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65 5 (2005) 1642-1646
39. Greulich H., Chen T., Feng W., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2 11 (2005) e313
40. Kobayashi S., Ji H., Yuza Y., et al. Analternativeinhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65 16 (2005) 7096-7101
41. Mitsudomi T., Kosaka T., Endoh H., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 11 (2005) 2513-2520
42. Takano T., Ohe Y., Sakamoto H., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 28 (2005) 6829-6837
43. Kobayashi S., Boggon T., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 8 (2005) 786-792
44. Pao W., Miller V., Politi K., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 3 (2005) e73
45. Balak M., Gong Y., Riely G., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12 21 (2006) 6494-6501
46. Daub H., Specht K., and Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 3 12 (2004) 1001-1010
47. Gorre M., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 5531 (2001) 876-880
48. Shah N., Nicoll J., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 2 (2002) 117-125
49. Shah N., Tran C., Lee F., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 5682 (2004) 399-401
50. Chen L., Trent J., Wu E., et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64 17 (2004) 5913-5919
51. Tamborini E., Bonadiman L., Greco A., et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127 1 (2004) 294-299
52. Cools J., De Angelo D., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 13 (2003) 1201-1214
53. Azam M., Latek R., and Daley G. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 6 (2003) 831-843
54. Kosaka T., Yatabe Y., Endoh H., et al. Analysis of epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12 19 (2006) 5764-5769
55. Jiang J., Greulich H., Janne P., et al. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65 19 (2005) 8968-8974
56. Cohen M., Williams G., Sridhara R., et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10 4 (2004) 1212-1218
57. Hidalgo M., Siu L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19 13 (2001) 3267-3279
58. Costa D., Halmos B., Kumar A., et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4 10 (2007) 1669-1679 discussion 1680.
59. Kwak E., Sordella R., Bell D., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102 21 (2005) 7665-7670
60. Yuza Y., Glatt K., Jiang J., et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther 6 5 (2007) 661-667
61. Ji H., Zhao X., Yuza Y., et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 103 20 (2006) 7817-7822
62. Ji H., Li D., Chen L., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9 6 (2006) 485-495
63. Li D., Shimamura T., Ji H., et al. Bronchialandperipheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12 1 (2007) 81-93
64. Wong K., Fracasso P., Bukowski R., et al. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. J Clin Oncol 24 18S (2006) 3018
65. Li D., Ambrogio L., Shimamura T., et al. BIBW 2992, an irreversible dual EGFR/HER2 inhibitor which is highly effective in lung cancer models. Oncogene (2008) online April 14th 2008.